OncoMatch/Clinical Trials/NCT06424340
MB-dNPM1-TCR.1 in Relapsed/Refractory AML
Is NCT06424340 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies MB-dNPM1-TCR.1 for leukemia, myeloid, acute.
Treatment: MB-dNPM1-TCR.1 — The goal of this Phase I/II, single arm, prospective, open label, dose escalation trial is to assess safety, feasibility and efficacy of ex vivo expanded autologous T cells genetically modified to express a T cell receptor (TCR) specific for dNPM1 peptides restricted to human leukocyte antigen (HLA) A\*02:01 in patients with relapsed or refractory AML.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Required: HLA-A a*02:01
Required: NPM1 mutation
Performance status
ECOG 0–3(Limited self-care)
Lab requirements
Kidney function
serum creatinine ≥ 2.0 × uln or egfr < 30 ml/min calculated according to the modified mdrd formula [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06424340 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require HLA-A?
Yes, HLA-A a*02:01 is a required biomarker for enrollment.
Does this trial require NPM1?
Yes, NPM1 mutation is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages